Table of Content

1 INTRODUCTION 47
1.1 STUDY OBJECTIVES 47
1.2 MARKET DEFINITION 47
1.2.1 INCLUSIONS & EXCLUSIONS 48
TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS & EXCLUSIONS 48
1.3 MARKET SCOPE 49
1.3.1 MARKETS COVERED 49
FIGURE 1 IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION 49
1.3.2 YEARS CONSIDERED 50
1.4 CURRENCY 50
1.5 LIMITATIONS 50
1.6 STAKEHOLDERS 51
1.7 SUMMARY OF CHANGES 51
1.7.1 RECESSION IMPACT 52
2 RESEARCH METHODOLOGY 53
2.1 RESEARCH DATA 53
FIGURE 2 IHC MARKET: RESEARCH DESIGN METHODOLOGY 53
2.1.1 SECONDARY DATA 54
2.1.2 PRIMARY DATA 54
FIGURE 3 IHC MARKET: BREAKDOWN OF PRIMARIES 55
2.2 MARKET ESTIMATION METHODOLOGY 56
FIGURE 4 IHC MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 56
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022 57
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 58
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 58
2.3 MARKET GROWTH RATE PROJECTIONS 59
FIGURE 7 IHC MARKET (SUPPLY SIDE): CAGR PROJECTIONS 60
FIGURE 8 IHC MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS 61
2.3.1 DATA TRIANGULATION 62
FIGURE 9 DATA TRIANGULATION METHODOLOGY 62
2.4 RESEARCH ASSUMPTIONS 63
2.5 RISK ANALYSIS 63
2.6 RECESSION IMPACT 63
TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 64
TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 64
TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 64
3 EXECUTIVE SUMMARY 65
FIGURE 10 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 65
FIGURE 11 IMMUNOHISTOCHEMISTRY MARKET SHARE, BY APPLICATION, 2022 66
FIGURE 12 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2023 VS. 2028 66
FIGURE 13 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL SNAPSHOT 67
4 PREMIUM INSIGHTS 68
4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW 68
FIGURE 14 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH 68
4.2 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SHARE, BY END USER AND COUNTRY (2022) 69
FIGURE 15 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC IHC MARKET IN 2022 69
4.3 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE 70
FIGURE 16 PRIMARY ANTIBODIES SEGMENT TO LEAD IHC ANTIBODIES MARKET DURING FORECAST PERIOD 70
5 MARKET OVERVIEW 71
5.1 INTRODUCTION 71
5.2 MARKET DYNAMICS 71
FIGURE 17 IHC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 71
TABLE 5 IHC MARKET: IMPACT ANALYSIS 72
5.2.1 DRIVERS 73
5.2.1.1 Rising geriatric population and growing prevalence of cancer 73
TABLE 6 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION (2022–2050) 73
FIGURE 18 CANCER INCIDENCE, BY REGION AND TYPE OF CANCER, 2020 74
5.2.1.2 Technological advancements in IHC 74
5.2.1.3 Availability of reimbursements for IHC tests 75
TABLE 7 CPT CODES FOR IHC PROCEDURES 75
5.2.1.4 Adoption of digital pathology 76
5.2.2 RESTRAINTS 77
5.2.2.1 Availability of alternative technologies 77
5.2.2.2 High degree of consolidation 78
TABLE 8 MAJOR ACQUISITIONS IN MARKET, 2020–2023 78
5.2.3 OPPORTUNITIES 78
5.2.3.1 Increasing demand for personalized medicine 78
FIGURE 19 GROWTH OF PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2022 79
5.2.3.2 Growing significance of companion diagnostics 79
5.2.3.3 Growth opportunities in emerging countries 80
5.2.3.4 Application of artificial intelligence in IHC 80
5.2.4 CHALLENGES 81
5.2.4.1 Product failures and recalls 81
5.2.4.2 Stringent regulatory requirements 81
5.2.4.3 Lack of standardization 81
5.3 ELEMENTS OF UNCERTAINTY IN IHC MARKET 82
FIGURE 20 IHC MARKET: SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH 82
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
FIGURE 21 REVENUE SHIFT & NEW REVENUE POCKETS FOR IHC PROVIDERS 83
5.5 PRICING ANALYSIS 83
TABLE 9 AVERAGE SELLING PRICE OF SOME IHC EQUIPMENT, REAGENTS, AND KITS (2022) 83
5.5.1 AVERAGE SELLING PRICE TRENDS 84
5.6 VALUE CHAIN ANALYSIS 84
FIGURE 22 VALUE CHAIN ANALYSIS OF IHC MARKET: RAW MATERIAL AND MANUFACTURING PHASE TO CONTRIBUTE MAXIMUM VALUE 84
5.6.1 RESEARCH AND PRODUCT DEVELOPMENT 85
5.7 ECOSYSTEM ANALYSIS 86
FIGURE 23 IHC MARKET: ECOSYSTEM ANALYSIS 86
TABLE 10 SUPPLY CHAIN ECOSYSTEM 86
5.8 TECHNOLOGY ANALYSIS 87
5.9 PATENT ANALYSIS 89
FIGURE 24 IHC MARKET: PATENT ANALYSIS, 2014–2023 89
TABLE 11 INDICATIVE LIST OF PATENTS IN IHC MARKET 90
5.10 REGULATORY ANALYSIS 91
5.10.1 US 91
TABLE 12 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 91
FIGURE 25 US: REGULATORY PROCESS FOR IVD DEVICES 92
5.10.2 CANADA 93
FIGURE 26 CANADA: REGULATORY PROCESS FOR IVD DEVICES 93
5.10.3 EUROPE 93
TABLE 13 EUROPE: CLASSIFICATION OF IVD DEVICES 93
FIGURE 27 EUROPE: REGULATORY PROCESS FOR IVD DEVICES 94
5.10.4 JAPAN 95
FIGURE 28 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 95
TABLE 14 JAPAN: CLASSIFICATION OF IVD REAGENTS 95
TABLE 15 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 96
5.10.5 CHINA 96
TABLE 16 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 96
5.10.6 INDIA 96
FIGURE 29 INDIA: REGULATORY PROCESS FOR IVD DEVICES 97
5.10.7 BRAZIL 97
FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 98
5.11 PORTER’S FIVE FORCES ANALYSIS 98
TABLE 17 IMPACT OF PORTER’S FIVE FORCES ANALYSIS ON IHC MARKET 98
5.11.1 THREAT OF NEW ENTRANTS 99
5.11.2 THREAT OF SUBSTITUTES 99
5.11.3 BARGAINING POWER OF BUYERS 99
5.11.4 BARGAINING POWER OF SUPPLIERS 99
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 100
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 100
TABLE 18 IMMUNOHISTOCHEMISTRY MARKET: LIST OF CONFERENCES AND EVENTS 100
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 101
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IMMUNOHISTOCHEMISTRY PRODUCTS 101
FIGURE 32 BUYING CRITERIA FOR IMMUNOHISTOCHEMISTRY PRODUCTS 101
6 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT 102
6.1 INTRODUCTION 103
TABLE 19 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 103
6.2 ANTIBODIES 103
TABLE 20 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 21 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 22 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 23 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 24 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 106
6.2.1 PRIMARY ANTIBODIES 106
6.2.1.1 Wide applications in diagnostics and research to support demand for primary antibodies 106
TABLE 25 IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 26 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 27 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 28 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 108
6.2.2 SECONDARY ANTIBODIES 108
6.2.2.1 Signal amplification through conjugation and comparatively easy manufacturing to fuel market 108
TABLE 29 IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 30 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 31 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 32 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 110
6.3 REAGENTS 111
TABLE 33 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 34 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 35 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 36 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 37 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 113
6.3.1 HISTOLOGICAL STAINS 113
6.3.1.1 Developments in concurrent detection of multiple antigenic sites and cancer disease progression studies to propel market 113
TABLE 38 IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 39 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 40 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 41 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2021–2028 (USD MILLION) 115
6.3.2 BLOCKING SERA AND REAGENTS 116
6.3.2.1 Blocking sera and reagents to prevent nonspecific binding and reduce background noise & potentially false-positive results 116
TABLE 42 IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 43 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 44 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 45 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 117
6.3.3 CHROMOGENIC SUBSTRATES 118
6.3.3.1 Chromogenic substrates segment to register highest growth during forecast period 118
TABLE 46 IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 47 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 48 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 49 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2021–2028 (USD MILLION) 119
6.3.4 FIXATION REAGENTS 120
6.3.4.1 North America projected to be largest market for fixation reagents 120
TABLE 50 IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 51 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 52 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 53 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 121
6.3.5 DILUENTS 122
6.3.5.1 Need of diluents for preparation of antibody solutions to promote market growth 122
TABLE 54 IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY REGION, 2021–2028 (USD MILLION) 122
TABLE 55 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 56 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 57 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2021–2028 (USD MILLION) 123
6.3.6 ORGANIC SOLVENTS 124
6.3.6.1 Organic solvents to prevent physical damage in specimens and improve clarity while visualizing tissue samples 124
TABLE 58 IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 59 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 60 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 61 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2021–2028 (USD MILLION) 125
6.3.7 PROTEOLYTIC ENZYMES 125
6.3.7.1 Proteolytic enzymes improve accessibility of target antibodies 125
TABLE 62 IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 63 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 64 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 65 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 127
6.3.8 OTHER REAGENTS 128
TABLE 66 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 67 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 68 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 69 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 130
6.4 EQUIPMENT 130
TABLE 70 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 71 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 72 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 73 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 74 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 132
6.4.1 SLIDE-STAINING SYSTEMS 132
6.4.1.1 Development of high-throughput staining systems to drive market growth 132
TABLE 75 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 76 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 77 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 78 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 134
6.4.2 TISSUE PROCESSING SYSTEMS 135
6.4.2.1 Technological advancements and need for automation due to lack of skilled workforce to fuel market 135
TABLE 79 IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 80 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 81 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 82 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 137
6.4.3 SLIDE SCANNERS 137
6.4.3.1 Development of advanced multiplexed IHC scanners to drive market growth 137
TABLE 83 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 84 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 85 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2021–2028 USD MILLION) 139
TABLE 86 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2021–2028 (USD MILLION) 139
6.4.4 OTHER EQUIPMENT 140
TABLE 87 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY REGION, 2021–2028 (USD MILLION) 140
TABLE 88 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 89 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 90 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 141
6.5 KITS 142
TABLE 91 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION, 2021–2028 (USD MILLION) 142
TABLE 92 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 93 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 94 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 95 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 144
6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS 144
6.5.1.1 Increasing focus on cancer research to fuel market growth 144
TABLE 96 IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 97 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 98 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 99 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 146
6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS 146
6.5.2.1 Increasing preclinical drug testing to boost market 146
TABLE 100 IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 101 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 102 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 103 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2021–2028 (USD MILLION) 148
7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION 149
7.1 INTRODUCTION 150
TABLE 104 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150
7.2 DIAGNOSTIC APPLICATIONS 150
TABLE 105 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 151
TABLE 106 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 107 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 108 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 109 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 153
7.2.1 CANCER 153
7.2.1.1 Rise in incidence rate of cancer and growing use of IHC tests for cancer diagnostics to drive market 153
TABLE 110 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS 154
TABLE 111 IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 112 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 113 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 114 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 156
7.2.2 INFECTIOUS DISEASES 157
7.2.2.1 Growing prevalence of infectious diseases and rising awareness of early diagnosis to propel market 157
TABLE 115 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS 157
TABLE 116 IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 158
TABLE 117 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 118 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 119 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 159
7.2.3 NEPHROLOGICAL DISEASES 160
7.2.3.1 Wide application of IHC in transplant rejection expected to support market growth 160
TABLE 120 IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2021–2028 (USD MILLION) 160
TABLE 121 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 122 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 123 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 162
7.2.4 AUTOIMMUNE DISEASES 162
7.2.4.1 Availability of numerous primary antibodies and rapid processing of results to drive market 162
TABLE 124 IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021–2028 (USD MILLION) 163
TABLE 125 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 126 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 127 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 164
7.2.5 NEUROLOGICAL DISEASES 165
7.2.5.1 Increasing global burden of neurological diseases to propel market growth 165
TABLE 128 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR CENTRAL NERVOUS SYSTEM 165
TABLE 129 IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2021–2028 (USD MILLION) 166
TABLE 130 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 131 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 132 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 167
7.2.6 OTHER DISEASES 167
TABLE 133 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY REGION, 2021–2028 (USD MILLION) 168
TABLE 134 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 135 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 136 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 169
7.3 RESEARCH APPLICATIONS 170
TABLE 137 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 170
TABLE 138 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 139 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 140 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 141 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 172
7.3.1 DRUG DEVELOPMENT & TESTING 172
7.3.1.1 Quantitative image analysis makes IHC techniques ideal for drug testing 172
TABLE 142 IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY REGION, 2021–2028 (USD MILLION) 173
TABLE 143 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 144 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 145 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2021–2028 (USD MILLION) 174
7.3.2 OTHER RESEARCH APPLICATIONS 175
TABLE 146 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 175
TABLE 147 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 148 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 149 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 176
7.4 FORENSIC APPLICATIONS 176
TABLE 150 IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 151 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 152 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 153 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 178
8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER 179
8.1 INTRODUCTION 180
TABLE 154 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 180
8.2 HOSPITALS & DIAGNOSTIC LABORATORIES 180
8.2.1 RISE IN SPECIALTY DIAGNOSTIC TESTS IN LABORATORIES AND IN-HOUSE DIAGNOSTIC PROCEDURES IN HOSPITALS TO DRIVE MARKET 180
TABLE 155 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 181
TABLE 156 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 157 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 158 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 182
8.3 ACADEMIC & RESEARCH INSTITUTES 183
8.3.1 GROWING APPLICATION OF IHC TESTS FOR DRUG DEVELOPMENT STUDIES TO POSITIVELY IMPACT MARKET GROWTH 183
TABLE 159 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 183
TABLE 160 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 161 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 162 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 184
8.4 OTHER END USERS 185
TABLE 163 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 185
TABLE 164 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 165 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 166 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 186
9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION 187
9.1 INTRODUCTION 188
TABLE 167 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2021–2028 (USD MILLION) 188
9.2 NORTH AMERICA 188
FIGURE 33 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT 189
TABLE 168 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 169 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 190
TABLE 170 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 171 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 172 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 173 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 174 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 192
TABLE 175 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 193
TABLE 176 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 177 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 194
9.2.1 US 194
9.2.1.1 Availability of reimbursements for FDA-approved immunohistochemistry products to promote market 194
TABLE 178 RECENT DEVELOPMENTS IN US IHC MARKET 195
TABLE 179 US: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 195
TABLE 180 US: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 181 US: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 182 US: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 183 US: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 184 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 197
TABLE 185 US: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 198<



9.3.4 ITALY 221
9.3.4.1 High incidence of cancer and rising geriatric population to support market growth in Italy 221
TABLE 235 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 222
TABLE 236 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 237 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 223
TABLE 238 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 223
TABLE 239 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 240 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 224
TABLE 241 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 224
TABLE 242 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 243 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 225
9.3.5 SPAIN 225
9.3.5.1 Spike in demand for personalized medicine to drive demand for IHC tests to find potential biomarkers 225
TABLE 244 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 226
TABLE 245 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 226
TABLE 246 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 247 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 248 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 249 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 228
TABLE 250 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 228
TABLE 251 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 252 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 229
9.3.6 REST OF EUROPE 229
TABLE 253 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 230
TABLE 254 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 255 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 256 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 257 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 258 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 232
TABLE 259 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 232
TABLE 260 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 233
TABLE 261 REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 233
9.3.7 EUROPE: RECESSION IMPACT 233
9.4 ASIA PACIFIC 234
FIGURE 34 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT 235
TABLE 262 RECENT DEVELOPMENTS IN ASIA PACIFIC IHC MARKET 236
TABLE 263 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 237
TABLE 264 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 237
TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 237
TABLE 266 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 267 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 268 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 269 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 239
TABLE 270 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 239
TABLE 271 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 240
TABLE 272 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 240
9.4.1 CHINA 240
9.4.1.1 Rise in product approvals and shift toward immunoassay diagnostics to fuel market growth 240
TABLE 273 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 241
TABLE 274 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 275 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 276 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 277 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 278 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 243
TABLE 279 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 244
TABLE 280 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 281 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 245
9.4.2 JAPAN 245
9.4.2.1 Advancing healthcare expenditure to drive market 245
TABLE 282 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 246
TABLE 283 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 284 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 247
TABLE 285 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 247
TABLE 286 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 248
TABLE 287 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 248
TABLE 288 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 248
TABLE 289 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 290 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 249
9.4.3 INDIA 249
9.4.3.1 High-end pathology and diagnostic services to propel market in India 249
TABLE 291 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 250
TABLE 292 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 250
TABLE 293 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 251
TABLE 294 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 251
TABLE 295 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 252
TABLE 296 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 252
TABLE 297 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 252
TABLE 298 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 253
TABLE 299 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 253
9.4.4 AUSTRALIA 253
9.4.4.1 Investment initiatives to drive market growth 253
TABLE 300 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 254
TABLE 301 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 254
TABLE 302 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 255
TABLE 303 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 255
TABLE 304 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 256
TABLE 305 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 256
TABLE 306 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 256
TABLE 307 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 257
TABLE 308 AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 257
9.4.5 SOUTH KOREA 257
9.4.5.1 Personalized medicine initiatives to fuel market growth 257
TABLE 309 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 258
TABLE 310 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 311 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 312 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 313 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 260
TABLE 314 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 260
TABLE 315 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 260
TABLE 316 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 261
TABLE 317 SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 261
9.4.6 REST OF ASIA PACIFIC 262
TABLE 318 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 262
TABLE 319 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 263
TABLE 320 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 263
TABLE 321 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 264
TABLE 322 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 264
TABLE 323 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 264
TABLE 324 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 265
TABLE 325 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 265
TABLE 326 REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 266
9.4.7 ASIA PACIFIC: RECESSION IMPACT 266
9.5 LATIN AMERICA 266
9.5.1 SPIKE IN INCIDENCE OF CANCER IN LATIN AMERICA TO BOOST MARKET 266
TABLE 327 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 267
TABLE 328 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 267
TABLE 329 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 330 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 331 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 269
TABLE 332 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 269
TABLE 333 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 269
TABLE 334 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 270
TABLE 335 LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 270
9.5.2 LATIN AMERICA: RECESSION IMPACT 270
9.6 MIDDLE EAST & AFRICA 271
9.6.1 GOVERNMENT INITIATIVES FOCUSED ON BOOSTING HEALTHCARE INFRASTRUCTURE DEVELOPMENT TO DRIVE MARKET 271
TABLE 336 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 271
TABLE 337 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 338 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 339 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2021–2028 (USD MILLION) 273
TABLE 340 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2021–2028 (USD MILLION) 273
TABLE 341 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 273
TABLE 342 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2021–2028 (USD MILLION) 274
TABLE 343 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 274
TABLE 344 MIDDLE EAST & AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021–2028 (USD MILLION) 275
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 275
10 COMPETITIVE LANDSCAPE 276
10.1 OVERVIEW 276
10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 276
FIGURE 35 IMMUNOHISTOCHEMISTRY MARKET: STRATEGIES ADOPTED BY KEY PLAYERS, 2020–2023 277
10.3 MARKET SHARE ANALYSIS 278
FIGURE 36 IMMUNOHISTOCHEMISTRY MARKET: SHARE ANALYSIS OF KEY PLAYERS (2022) 278
10.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 279
FIGURE 37 IMMUNOHISTOCHEMISTRY MARKET: REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS FOR PAST FIVE YEARS 279
10.5 COMPANY EVALUATION QUADRANT 280
10.5.1 STARS 280
10.5.2 EMERGING LEADERS 280
10.5.3 PERVASIVE PLAYERS 280
10.5.4 PARTICIPANTS 280
FIGURE 38 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT, 2022 281
10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 282
10.6.1 PROGRESSIVE COMPANIES 282
10.6.2 STARTING BLOCKS 282
10.6.3 RESPONSIVE COMPANIES 282
10.6.4 DYNAMIC COMPANIES 282
FIGURE 39 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022 283
10.7 COMPANY PRODUCT FOOTPRINT 284
TABLE 345 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT PORTFOLIO ANALYSIS (2022) 284
10.8 COMPANY REGIONAL FOOTPRINT 285
TABLE 346 IMMUNOHISTOCHEMISTRY MARKET: REGIONAL REVENUE MIX (2022) 285
10.9 COMPETITIVE BENCHMARKING OF START-UPS/SMES 286
TABLE 347 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY START-UPS/SMES 286
10.10 COMPETITIVE SCENARIO 287
TABLE 348 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT LAUNCHES, JANUARY 2020–MAY 2023 287
TABLE 349 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2020–MAY 2023 288
TABLE 350 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS, JANUARY 2020–MAY 2023 289
11 COMPANY PROFILES 290
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
11.1 KEY PLAYERS 290
11.1.1 F. HOFFMANN-LA ROCHE AG 290
TABLE 351 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 290
FIGURE 40 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022) 291
11.1.2 DANAHER CORPORATION 299
TABLE 352 DANAHER CORPORATION: BUSINESS OVERVIEW 299
FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 300
11.1.3 AGILENT TECHNOLOGIES, INC. 306
TABLE 353 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 306
FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 307
11.1.4 THERMO FISHER SCIENTIFIC, INC. 314
TABLE 354 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 314
FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 315
11.1.5 MERCK KGAA 320
TABLE 355 MERCK KGAA: BUSINESS OVERVIEW 320
FIGURE 44 MERCK KGAA: COMPANY SNAPSHOT (2022) 321
11.1.6 BIO-RAD LABORATORIES, INC. 330
TABLE 356 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 330
FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 331
11.1.7 BIO-TECHNE CORPORATION 336
TABLE 357 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 336
FIGURE 46 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022) 337
11.1.8 ABCAM PLC 340
TABLE 358 ABCAM PLC: BUSINESS OVERVIEW 340
FIGURE 47 ABCAM PLC: COMPANY SNAPSHOT (2022) 341
11.1.9 BECTON, DICKINSON AND COMPANY 346
TABLE 359 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 346
FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 347
11.1.10 PERKINELMER, INC. 353
TABLE 360 PERKINELMER, INC.: BUSINESS OVERVIEW 353
FIGURE 49 PERKINELMER, INC.: COMPANY SNAPSHOT (2022) 354
11.1.11 TAKARA BIO, INC. 357
TABLE 361 TAKARA BIO, INC.: BUSINESS OVERVIEW 357
FIGURE 50 TAKARA BIO, INC.: COMPANY SNAPSHOT (2022) 358
11.1.12 PHC HOLDINGS CORPORATION 361
TABLE 362 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW 361
FIGURE 51 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 362
11.1.13 CELL SIGNALING TECHNOLOGY, INC. 368
TABLE 363 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW 368
11.1.14 BIO SB, INC. 372
TABLE 364 BIO SB, INC.: BUSINESS OVERVIEW 372
11.1.15 MILTENYI BIOTEC 377
TABLE 365 MILTENYI BIOTEC: BUSINESS OVERVIEW 377
11.1.16 SAKURA FINETEK JAPAN CO., LTD. 381
TABLE 366 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW 381
11.1.17 ENZO BIOCHEM, INC. 387
TABLE 367 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW 387
FIGURE 52 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022) 388
11.1.18 ORIGENE TECHNOLOGIES, INC. 393
TABLE 368 ORIGENE TECHNOLOGIES, INC.: BUSINESS OVERVIEW 393
11.2 OTHER PLAYERS 396
11.2.1 EAGLE BIOSCIENCES, INC. 396
TABLE 369 EAGLE BIOSCIENCES, INC.: BUSINESS OVERVIEW 396
11.2.2 BIOCARE MEDICAL, LLC 397
TABLE 370 BIOCARE MEDICAL, LLC: BUSINESS OVERVIEW 397
11.2.3 ELABSCIENCE BIOTECHNOLOGY, INC. 398
TABLE 371 ELABSCIENCE BIOTECHNOLOGY, INC.: COMPANY OVERVIEW 398
11.2.4 BIOGENEX LABORATORIES 400
TABLE 372 BIOGENEX LABORATORIES: COMPANY OVERVIEW 400
11.2.5 DIAGNOSTIC BIOSYSTEMS, INC. 401
TABLE 373 DIAGNOSTIC BIOSYSTEMS, INC.: BUSINESS OVERVIEW 401
11.2.6 HISTO-LINE LABORATORIES 402
TABLE 374 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW 402
11.2.7 ROCKLAND IMMUNOCHEMICALS, INC. 403
TABLE 375 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW 403
11.2.8 GENEMED BIOTECHNOLOGIES, INC. 404
TABLE 376 GENEMED BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW 404
11.2.9 CANDOR BIOSCIENCE GMBH 406
TABLE 377 CANDOR BIOSCIENCE GMBH: BUSINESS OVERVIEW 406
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 407
12.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 411
12.2 CUSTOMIZATION OPTIONS 413
12.3 RELATED REPORTS 413
12.4 AUTHOR DETAILS 414